USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated

10 Feb 2025 Evaluate

United States Food and Drugs Administration (USFDA) has classified routine current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s Bengaluru manufacturing facility, as Voluntary Action Indicated (VAI). USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1520.00 -1.20 (-0.08%)
05-Dec-2025 15:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1803.50
Dr. Reddys Lab 1274.50
Cipla 1520.00
Zydus Lifesciences 930.75
Lupin 2098.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×